Gleason score and metastatic prostate cancer; risk for 4-year mortality

It is difficult to accurately interpret a set of data just published that was designed to assess the relationship between 4-year survival and Gleason score at diagnosis in men initially diagnosed with metastatic prostate cancer. … READ MORE …

Your blood type may affect your risk for prostate cancer mortality

Perhaps the most fascinating paper to be presented this year at the Genitourinary Cancers Symposium has to do with blood typing and risk for lethal prostate cancer. … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

Does regional analgesia reduce risk for cancer progression when added to general anesthesia?

Based on a retrospective analysis of data from > 1,600 patients treated by radical prostatectomy at the Mayo Clinic, a newly published paper suggests that supplementing general anesthesia with regional (neuraxial) analgesia may lower risk for disease recurrence. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Mediterranean diet and overall mortality after diagnosis with non-metastatic prostate cancer

An article in European Urology has shown that a heart-healthy, “Mediterranean” diet lowers the overall mortality of men diagnosed with prostate cancer. However, the study also shows that this type of diet has no impact on risk for a diagnosis of advanced or lethal prostate cancer or on prostate cancer progression or prostate cancer-specific mortality after diagnosis. … READ MORE …

Finasteride prevents 30 percent of low-risk prostate cancers (with no added risk of mortality)

An article published today in the New England Journal of Medicine and based on a re-visitation of data from the Prostate Cancer Prevention Trial (PCPT) suggests that finasteride may prevent as many as 30 percent of cases of low-risk prostate cancer without any increase in mortality. … READ MORE …

How low is the risk for Gleason score progression over time?

A new study report in Cancer Research suggests that: (a) prostate cancer aggressiveness may be established when the initial tumor is formed and not alter over time; (b) active surveillance or similar monitoring strategies really are the most appropriate initial management option for men with low-grade, low-risk cancer (potentially regardless of their age at diagnosis). … READ MORE …

Non-prostate cancer-specific mortality rates in a cohort of > 3,000 patients

The issue of how long a man who is newly diagnosed with localized prostate cancer is likely to live before he dies a natural death from other causes is a crucial element in the decision whether to undergo treatment (and how aggressive that treatment may need to be). … READ MORE …

The over-treatment of low-risk disease in the Medicare community

So there’s a lot of media coverage this morning about an article in the Journal of the American Medical Association suggesting that, here in the USA, more men with low-risk forms of localized prostate cancer are getting more expensive types of treatment for their cancer (and that much of this treatment may be of dubious value). … READ MORE …

Does 120-day mortality after prostate biopsy outweigh any possible benefit of screening?

Back in 2008, Gallina et al. demonstrated that the risk for mortality at 120 days after a prostate biopsy was of the order of 2 deaths per 1,000 prostate biopsies, and historically this is the only population-based study ever to assess this risk. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

Statin use before diagnosis associated with less risk of prostate cancer-specific mortality

According to an article just published on line in Prostate, taking statins before a diagnosis of prostate cancer lowers risk for prostate cancer-specific mortality (but does not lower risk for progression/recurrence of prostate cancer after first-line treatment). … READ MORE …

Gene copy number alteration analysis and risk for prostate cancer-specific mortality

A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …

Screening smarter — more supportive PSA data from the Malmö Preventive Project

So a new paper just published in the British Medical Journal offers further evidence that a PSA test offered to men between 45 and 49 years of age can predict lifetime risk for prostate cancer with a significant level of accuracy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers